Medivation Inc. and partner Astellas Pharma Inc. are fully prepared for a U.S. launch of Xtandi (enzalutamide) for metastatic castration-resistant prostate cancer despite an approval that came three months ahead of the anticipated action date.
FDA made the announcement the afternoon of Aug. 31, as the U.S. prepared to celebrate the Labor Day long weekend
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?